Supporting the global health response to COVID-19
The COVID-19 pandemic continues to disrupt global supply chains for quality medical products. Learn how USP's work in low- and middle-income countries helps mitigate potential shortages, protects patients from the proliferation of substandard and falsified medical products, and assures the quality of COVID-19 related products. Visit USP's website to learn more about our work to fight COVID-19.
USP offers COVID-19 guidance to African regulatory authorities  

USP’s Lawrence Evans spoke to African Leadership Magazine about the impact of the COVID-19 pandemic in Africa, USP's work with regulators to protect patients from poor-quality medical products, and how to advance pharmaceutical manufacturing on the continent.
Africa Pharma Conference insights on local pharmaceutical manufacturing
USP’s Emily Kaine was keynote speaker in two recent webinars organized by Africa Pharma Conference and AUDA-NEPAD to facilitate conversations on galvanizing African manufacturers to supply pharmaceutical and medical products during the COVID-19 pandemic.

Here are the links to the post-webinar summaries:

Interactive dashboard of investigational COVID-19 drugs
Ten international pharmacopeias, including USP, came together through the World Health Organization to publish an interactive dashboard of active pharmaceutical ingredients and monographs for existing generic drugs being investigated as COVID-19 treatments.
Lessons from Ebola
USP’s Farouk Umaru discussed opportunities to strengthen health systems and clinical labs to help prepare for future outbreaks in a new blog post for Quality Matters.
Importance of medicine quality in achieving universal health coverage
New research supported by the USAID-funded PQM program examined the association between universal health coverage (UHC) and medicine quality in the context of essential medicines in low- and middle-income countries using data on substandard and falsified medicines prevalence and UHC indicators. The study demonstrates that assuring the quality of medicines not only saves lives, but also saves money for families, health systems, and economies.

Read the article published in PLOS ONE by researchers at USP and the University of North Carolina.
New USP technology review
USP's Technology Review Program evaluates medicine screening technologies that can help rapidly identify substandard and falsified medicines in the field for full laboratory testing. Read USP's new evaluation of the Smiths Detection Target-ID, a portable Fourier- transform infrared (FTIR) spectrometer, which assesses the technology's ability be used as a first-line screening technology to identify the presence of active pharmaceutical ingredients in drug products.